[Translation] A trial evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity and preliminary antitumor activity of CC312 in adult patients with relapsed/refractory CD19-positive B-cell hematological malignancies Multicenter phase I clinical study
(1)评估CC312在复发/难治性CD19阳性的B细胞性非霍奇金淋巴瘤和B淋巴细胞白血病患者中的安全性和耐受性;
(2)探索CC312的剂量限制性毒性(DLT),并确定CC312在复发/难治CD19阳性的B细胞性非霍奇金淋巴瘤患者中的最大耐受剂量(MTD)和/或II期推荐剂量(RP2D)。
[Translation] (1) To evaluate the safety and tolerability of CC312 in patients with relapsed/refractory CD19-positive B-cell non-Hodgkin's lymphoma and B-lymphocytic leukemia;
(2) Explore the dose-limiting toxicity (DLT) of CC312, and determine the maximum tolerated dose (MTD) and/or phase II recommendation of CC312 in patients with relapsed/refractory CD19-positive B-cell non-Hodgkin's lymphoma dose (RP2D).